Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission
- 1 December 2003
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (18) , 2665-2667
- https://doi.org/10.1097/00002030-200312050-00015
Abstract
Zidovudine monotherapy is used to reduce perinatal HIV transmission in women with low viral loads. There are few data on the risk of drug resistance in this select cohort of women. We determined the prevalence of newly acquired mutations conferring reduced sensitivity to zidovudine after exposure during pregnancy, and found that the development of mutations was uncommon and was restricted to women treated before 1998 who had higher baseline viral loads than those currently recommended monotherapy.Keywords
This publication has 5 references indexed in Scilit:
- Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmissionHIV Medicine, 2001
- HIV-1 genotypic zidovudine drug resistance and the risk of maternal–infant transmission in the Women and Infants Transmission Study*AIDS, 2000
- Maternal Viral Genotypic Zidovudine Resistance and Infrequent Failure of Zidovudine Therapy to Prevent Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Pediatric AIDS Clinical Trials Group Protocol 076The Journal of Infectious Diseases, 1998
- Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 InfectionAnnals of Internal Medicine, 1997
- Quantification of HIV-1 RNA in Plasma: Comparable Results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV Monitor TestJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996